Inhibition of human umbilical vein endothelial cell proliferation by the CXC chemokine, platelet factor 4 (PF4), is associated with impaired downregulation of p21(Cip1/WAF1)

Blood

Volumn 93, Issue 1, 1999, Pages 25-33

  Gentilini, Grazia ^a   Kirschbaum, Nancy E ^a   Augustine, James A ^a   Aster, Richard H ^a   Visentin, Gian Paolo ^a  

^a BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; PROTEIN P21; RETINOBLASTOMA PROTEIN; THROMBOCYTE FACTOR 4;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

EID: 0032910176     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.1.25     Document Type: Article

References (79)

1. Oppenheim JJ, Zachariae CO, Mukaida N, Matsushima K: Properties of the novel proinflammatory supergene "intercrine" cytokine family. Ann Rev Immunol 9:617, 1991
2. Rollins BJ: Chemokines. Blood 90:909, 1997
3. Szabo MC, Soo KS, Zlotnik A, Schall TJ: Chemokine class differences in binding to the Duffy antigen-erythrocyte chemokine receptor. J Biol Chem 270:25348, 1995
4. Busch C, Dawes J, Pepper DS, Wasteson A: Binding of platelet factor 4 to cultured human umbilical vein endothelial cells. Thromb Res 19:129, 1980
5. Busch C, Owen WG: Identification in vitro of an endothelial cell surface cofactor for antithrombin III. Parallel studies with isolated perfused rat hearts and microcarrier cultures of bovine endothelium. J Clin Invest 69:726, 1982
6. Rybak ME, Gimbrone MAJ, Davies PF, Handin RI: Interaction of platelet factor four with cultured vascular endothelial cells. Blood 73:1534, 1989
7. Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U: Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 218:725, 1984
8. Marcum JA, McKenney JB, Rosenberg RD: Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparinlike molecules bound to the endothelium. J Clin Invest 74:341, 1984
9. Stern D, Nawroth P, Marcum J, Handley D, Kisiel W, Rosenberg R. Stem: Interaction of antithrombin III with bovine aortic segments. Role of heparin in binding and enhanced anticoagulant activity. J Clin Invest 75:272, 1985
10. Dudek AZ, Pennell CA, Decker TD, Young TA, Key NS, Slungaard A: Platelet factor 4 binds to glycanated forms of thrombomodulin and to protein C - A potential mechanism for enhancing generation of activated protein C. J Biol Chem 272:31785, 1997
11. Maione TE, Gray GS, Petro J, Hunt AJ, Donner AL, Bauer SI, Carson HF, Sharpe RJ: Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 247:77, 1990
12. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, Dzuiba J, Van DJ, Walz A, Marriott D: The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 270:27348, 1995
13. Han ZC, Sensebe L, Abgrall JF, Briere J: Platelet factor 4 inhibits human megakaryocytopoiesis in vitro. Blood 75:1234, 1990
14. Broxmeyer HE, Sherry B, Cooper S, Lu L, Maze R, Beckmann MP, Cerami A, Ralph P: Comparative analysis of the human macrophage inflammatory protein family of cytokines (chemokines) on proliferation of human myeloid progenitor cells. Interacting effects involving suppression, synergistic suppression, and blocking of suppression. J Immunol 150:3448, 1993
15. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353, 1996
16. Boehm T, Folkman J, Browder T, O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance [see comments]. Nature 390:404, 1997
17. Kolber DL, Knisely TL, Maione TE: Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4. J Natl Cancer Inst 87:304, 1995
18. Maione TE, Gray GS, Hunt AJ, Sharpe RJ: Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity. Cancer Res 51:2077, 1991
19. Sharpe RJ, Byers HR, Scott CF, Bauer SI, Maione TE: Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J Natl Cancer Inst 82:848, 1990
20. Tanaka T, Manome Y, Wen P, Kufe DW, Fine HA: Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nature Med 3:437, 1997
21. Belman N, Bonnem EM, Harvey HA, Lipton A: Phase I trial of recombinant platelet factor 4 (rPF4) in patients with advanced colorectal carcinoma. Invest New Drugs 14:387, 1996
22. Hansell P, Maione TE, Borgstrom P: Selective binding of platelet factor 4 to regions of active angiogenesis in vivo. Am J Physiol 269:H829, 1995
23. Watson JB, Getzler SB, Mosher DF: Platelet factor 4 modulates the mitogenic activity of basic fibroblast growth factor. J Clin Invest 94:261, 1994
24. Gupta SK, Singh JP: Inhibition of endothelial cell proliferation by platelet factor-4 involves a unique action on S phase progression. J Cell Biol 127:1121, 1994
25. Morgan DO: Principles of CDK regulation. Nature 374:131, 1995
26. Planas-Silva MD, Weinberg RA: The restriction point and control of cell proliferation. Curr Opin Cell Biol 9:768, 1997
27. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81:323, 1995
28. Sherr CJ: G1 phase progression: Cycling on cue [see comments]. Cell 79:551, 1994
29. Sherr CJ: Cancer cell cycles. Science 274:1672, 1996
30. Sherr CJ: D-type cyclins. Trends Biochem Sci 20:187, 1995
31. Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9:1149, 1995
32. Harper JW, Elledge SJ: Cdk inhibitors in development and cancer. Curr Opin Genet Dev 6:56, 1996
33. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF: Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Nat Acad Sci USA 92:5545, 1995
34. Mandal M, Bandyopadhyay D, Goepfert TM, Kumar R: Interferon-inJuces expression of cyclin-dependent kinase-inhibitors p21WAF1 and p27Kip1 that prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK). Oncogene 16:217, 1998
35. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A: p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 8:9, 1994
36. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805, 1993
37. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75:817, 1993
38. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases [see comments]. Nature 366:701, 1993
39. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Connell-Crowley L, Swindell E: Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 6:387, 1995
40. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P: Mice lacking p21ClP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82:675, 1995
41. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D: Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 54:3391, 1994
42. Zeng YX, el-Deiry WS: Regulation of p21WAF1/CIP1 expression by p53-independent pathways. Oncogene 12:1557, 1996
43. Waga S, Hannon GJ, Beach D, Stillman B: The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA [see comments]. Nature 369:574, 1994
44. Visentin GP, Ford SE, Scott JP, Aster RH: Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 completed with heparin or bound to endothelial cells. J Clin Invest 93:81, 1994
45. Poncz M, Surrey S, LaRocco P, Weiss MJ, Rappaport EF, Conway TM, Schwartz E: Cloning and characterization of platelet factor 4 cDNA derived from a human erythroleukemic cell line. Blood 69:219, 1987
46. Barbieri B, Balconi G, Dejana E, Donati MB: Evidence that vascular endothelial cells can induce the retraction of fibrin clots. Proc Soc Exp Biol Med 168:204, 1981
47. Balconi G, Dejana E: Cultivation of endothelial cells: Limitations and perspectives. Med Biol 64:231, 1986
48. Sato Y, Abe M, Takaki R: Platelet factor 4 blocks the binding of basic fibroblast growth factor to the receptor and inhibits the spontaneous migration of vascular endothelial cells. Biochem Biophys Res Commun 172:595, 1990
49. Bono F, Rigon P, Lamarche I, Savi P, Salel V, Herbert, JM: Heparin inhibits the binding of basic fibroblast growth factor to cultured human aortic smooth-muscle cells. Biochem J 326:661, 1997
50. Laslett AL, McFarlane JR, Risbridger GP: Developmental response by Leydig cells to acidic and basic fibroblast growth factor. J Steroid Biochem Mol Biol 60:171, 1997
51. Perollet C, Han ZC, Savona C, Caen JP, Bikfalvi A: Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. Blood 91:3289, 1998
52. Aviezer D, Yayon A: Heparin-dependent binding and autophosphorylation of epidermal growth factor (EGF) receptor by heparin-binding EGF-like growth factor but not by EGF. Proc Natl Acad Sci USA 91:12173, 1994
53. Mihara K, Cao XR, Yen A, Chandler S, Driscoll B, Murphree AL, Ang A, Fung YK: Cell cycle-dependent regulation of phosphorylation of the human retinoblastoma gene product. Science 246:1300, 1989
54. DeCaprio JA, Ludlow JW, Lynch D, Furukawa Y, Griffin J, Piwnica-Worms H, Huang CM, Livingston DM: The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell 58:1085, 1989
55. Lundberg AS, Weinberg RA: Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 18:753, 1998
56. Dumont FJ, Su Q: Mechanism of action of the immunosuppressant rapamycin. Life Sci 58:373, 1996
57. Wiederrecht GJ, Sabers CJ, Brunn GJ, Martin MM, Dumont FJ, Abraham RT: Mechanism of action of rapamycin: New insights into the regulation of G1-phase progression in eukaryotic cells. Prog Cell Cycle Res 1:53, 1995
58. Luster AD, Greenberg SM, Leder P: The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med 182:219, 1995
59. Bikfalvi A, Javerzat S, Perollet C, Savona C: Angiogenesis and cancer. Bulletin du Cancer 84:885, 1997
60. Gengrinovitch S, Greenberg SM, Cohen T, Gitay-Goren H, Rockwell P, Maione TE, Levi BZ, Neufeld G: Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms. J Biol Chem 270:15059, 1995
61. Brown KJ, Parish CR: Histidine-rich glycoprotein and platelet factor 4 mask heparan sulfate proteoglycans recognized by acidic and basic fibroblast growth factor. Biochemistry 33:13918, 1994
62. Li CY, Suardet L, Little JB: Potential role of WAF1/Cip1/p21 as a mediator of TGF-beta cytoinhibitory effect. J Biol Chem 270:4971, 1995
63. Chen CY, Shyu AB: AU-rich elements: Characterization and importance in mRNA degradation. Trends Biochem Sci 20:465, 1995
64. Li XS, Rishi AK, Shao ZM, Dawson MI, Jong L, Shroot B, Reichert U, Ordonez J, Fontana JA: Posttranscriptional regulation of p21WAF1/CIP1 expression in human breast carcinoma cells. Cancer Res 56:5055, 1996
65. Schwaller J, Koeffler HP, Niklaus G, Loetscher P, Nagel, Fey MF, Tobler A: Posttranscriptional stabilization underlies p53-independent induction of p21WAF1/CIP1/SDI1 in differentiating human leukemic cells. J Clin Invest 95:973, 1995
66. Gorospe M, Wang X, Holbrook NJ: p53-dependent elevation of p21Waf1 expression by UV light is mediated through mRNA stabilization and involves a vanadate-sensitive regulatory system. Mol Cell Biol 18:1400, 1998
67. Keane MP, Arenberg DA. Moore BB, Addison CL, Strieter RM: CXC Chemokines and angiogenesis/angiostasis. Proc Assoc Am Phys 110:288, 1998
68. Schlessinger J, Lax I, Lemmon M: Regulation of growth factor activation by proteoglycans: What is the role of the low affinity receptors? Cell 83:357, 1995
69. Stringer SE, Gallagher JT: Specific binding of the chemokine platelet factor 4 to heparan sulfate. J Biol Chem 272:20508, 1997
70. Oh ES, Woods A, Couchman JR: Syndecan-4 proteoglycan regulates the distribution and activity of protein kinase C. J Biol Chem 272:8133, 1997
71. Oh ES, Woods A, Lim ST, Theibert AW, Couchman JR: Syndecan-4 proteoglycan cytoplasmic domain and phosphatidylinositol 4,5-bisphosphate coordinately regulate protein kinase C activity. J Biol Chem 273:10624, 1998
72. Middleton J, Neil S, Wintle J, Clark-Lewis I, Moore H, Lam C, Auer M, Hub E, Rot A: Transcytosis and surface presentation of IL-8 by venular endothelial cells. Cell 91:385, 1997
73. Peiper SC, Wang ZX, Neote K, Martin AW, Showell HJ, Conklyn MJ, Ogborne, Hadley TJ, Lu ZH, Hesselgesser J: The Duffy antigen/ receptor for chemokines (DARC) is expressed in endothelial cells of Duffy negative individuals who lack the erythrocyte receptor. J Exp Med 181:1311, 1995
74. Chaudhuri A, Nielsen S, Elkjaer ML, Zbrzezna V, Fang F, Pogo AO: Detection of Duffy antigen in the plasma membranes and caveolae of vascular endothelial and epithelial cells of nonerythroid organs [see comments]. Blood 89:701, 1997
75. Hadley TJ, Peiper SC: From malaria to chemokine receptor: The emerging physiologic role of the Duffy blood group antigen. Blood 89:3077, 1997
76. Yoshimitsu K, Wright KC, Wallace S, Charnsangavej C, Mavligit GM: Hepatic arterial infusion of recombinant platelet factor-4 suppresses metastases to the lungs from tumors implanted into the livers of rabbits. Cancer 75:2435, 1995
77. Gupta SK, Hassel T, Singh JP: A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. Proc Natl Acad Sci USA 92:7799, 1995
78. Lecomte-Raclet L, Alemany M, Sequira-Le GA, Amiral J, Quentin G, Vissac AM, Caen JP, Han ZC: New insights into the negative regulation of hematopoiesis by chemokine platelet factor 4 and related peptides. Blood 91:2772, 1998
79. Cao Y, O'Reilly MS, Marshall B, Flynn E, Ji RW, Folkman: Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest 101:1055, 1998